Replimune Group, Inc. (NASDAQ:REPL) Holdings Reduced by Redmile Group LLC

Redmile Group LLC lessened its stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 14.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,781,183 shares of the company's stock after selling 780,913 shares during the period. Replimune Group comprises approximately 3.1% of Redmile Group LLC's investment portfolio, making the stock its 8th biggest holding. Redmile Group LLC owned approximately 6.99% of Replimune Group worth $52,402,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Nisa Investment Advisors LLC grew its holdings in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company's stock worth $45,000 after acquiring an additional 4,946 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Replimune Group in the 2nd quarter worth approximately $57,000. Erste Asset Management GmbH bought a new position in shares of Replimune Group during the third quarter valued at approximately $133,000. Arizona State Retirement System purchased a new position in Replimune Group during the second quarter valued at approximately $108,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Replimune Group by 82.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company's stock valued at $144,000 after buying an additional 5,926 shares during the period. Hedge funds and other institutional investors own 92.53% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on REPL. JPMorgan Chase & Co. upped their target price on Replimune Group from $14.00 to $17.00 and gave the stock an "overweight" rating in a report on Tuesday, September 24th. Roth Capital raised Replimune Group to a "strong-buy" rating in a research report on Tuesday, August 27th. HC Wainwright reiterated a "buy" rating and issued a $17.00 target price on shares of Replimune Group in a research note on Friday, November 22nd. Roth Mkm started coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They set a "buy" rating and a $17.00 price target for the company. Finally, BMO Capital Markets raised their price target on shares of Replimune Group from $14.00 to $18.00 and gave the company an "outperform" rating in a report on Friday, November 22nd. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $17.29.

Replimune Group Stock Down 0.9 %

Shares of REPL stock traded down $0.12 during trading hours on Thursday, reaching $13.05. 647,373 shares of the company's stock were exchanged, compared to its average volume of 1,061,681. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a market cap of $892.88 million, a PE ratio of -4.28 and a beta of 1.26. The stock's fifty day moving average price is $12.06 and its two-hundred day moving average price is $10.16.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. Research analysts predict that Replimune Group, Inc. will post -2.99 EPS for the current year.

Insider Activity

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares of the company's stock, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 8.80% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.